Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Effectors and potential targets selectively upregulated in human KRAS-mutant lung adenocarcinomas.

Scientific reports - 15 Jun 2016

Li Jinyu, Sordella Raffaella, Powers Scott

Abstract excerpt

Genetic and proteomic analysis of human tumor samples can provide an important compliment to information obtained from model systems. Here we examined protein and gene expression from the Cancer Genome and Proteome Atlases (TCGA and TCPA) to characterize proteins and protein-coding genes that are selectively upregulated in KRAS-mutant lung adenocarcinomas. Phosphoprotein activation of several MAPK signaling...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma of Lung
Share to MAP Kinase Signaling System
Share to Proto-Oncogene Proteins c-met

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Pyruvate Dehydrogenase Acetyl-Transferring Kinase

Share to raf Kinases

Share to Receptor-Like Protein Tyrosine Phosphatases, Class 2

Share to Sequence Analysis, RNA

Share to Up-Regulation

Source

Open in PubMed Open full text

Identifiers

PMID: 27301828
DOI: 10.1038/srep27891
PMCID: PMC4908391

Genes

KRAS
BRAF
PDK1
PTPRE
PTPRM

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Effectors and potential targets selectively upregulated in human KRAS-mutant lung adenocarcinomas.PMID 27301828Read ↗

Effectors and potential targets selectively upregulated in human KRAS-mutant lung adenocarcinomasSemantic proximity Read ↗

Functional signaling pathway analysis of lung adenocarcinomas identifies novel therapeutic targets for KRAS mutant tumors.Semantic proximity Read ↗

Wild-Type KRAS Allele Effects on Druggable Targets in KRAS Mutant Lung Adenocarcinomas.Semantic proximity Read ↗

Identification of subsets of actionable genetic alterations in KRAS-mutant lung cancers using association rule mining.Semantic proximity Read ↗

Identification of Subsets of Genetic Alterations in KRAS-mutant Lung Cancer using Association Rule MiningSemantic proximity Read ↗

Phosphoproteomics Identifies Oncogenic Ras Signaling Targets and Their Involvement in Lung AdenocarcinomasSemantic proximity Read ↗

Determining the ERK-regulated phosphoproteome driving KRAS-mutant cancer.Semantic proximity Read ↗

KRAS-Mutant Lung Cancers in the Era of Targeted Therapy.Semantic proximity Read ↗

Gene expression profiling of epidermal growth factor receptor/KRAS pathway activation in lung adenocarcinoma.Semantic proximity Read ↗

Defining the KRAS- and ERK-dependent transcriptome in KRAS-mutant cancers.Semantic proximity Read ↗

ERK-dependent protein phosphorylation in KRAS-mutant cancer: a mix of the expected and surprising.Semantic proximity Read ↗

Co-occurring genomic alterations define major subsets of KRAS-mutant lung adenocarcinoma with distinct biology, immune profiles, and therapeutic vulnerabilities.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.